Technology

The receptors under investigation at Orphagen Pharmaceuticals have been implicated in immunity, sleep disorders and metabolic disease. HTS screening has yielded modulators with properties suitable for medicinal chemistry exploration and lead molecules derived from these are under intensive investigation.


Orphagen's technology position:

- Orphagen scientists have demonstrated that certain unexplored orphan nuclear receptors are viable targets for drug discovery.
- The Company is developing a strong intellectual property position.
- Nuclear receptors respond to small molecules—the kind of therapeutic entity most suitable for oral or topical use.


About nuclear receptors

Nuclear receptors are highly successful drug targets, generating $12 billion in annual U.S. sales. They are transcription factors that are directly regulated by small molecules, and they have very diverse therapeutic uses. The unexplored orphan nuclear receptors have the potential to generate novel therapeutic agents and open new pharmaceutical markets.